DAVID GOLDSTEIN
Psychologist in Durham, NC
License number
Pennsylvania PS003669L
Category
Psychology
Type
Psychologist
Address
Address
2
Durham, NC 27706
Pennsylvania
Pennsylvania
Personal information
See more information about DAVID GOLDSTEIN at radaris.comName
Address
Phone
4630 Fir Dr, Nazareth, PA 18064
55 Holiday Dr, Hawley, PA 18428
5400 Reunion Pt, Raleigh, NC 27609
52 Garetta St APT 409A, Pittsburgh, PA 15217
927 Hancock St, Philadelphia, PA 19123
Professional information
See more information about DAVID GOLDSTEIN at trustoria.com
Genetic Markers Associated With Interferon-Alpha Response
Genetic Markers Associated With Interferon-Alpha Response
US Patent:
2013025, Sep 26, 2013
Filed:
May 30, 2013
Appl. No.:
13/905987
Inventors:
Jacques Fellay - St. Maurice, CH
Dongliang Ge - Foster City CA, US
David B. Goldstein - Durham NC, US
John G. McHutchison - Chapel Hill NC, US
Ping Qiu - Edison NJ, US
Kevin Shianna - Durham NC, US
Jason S. Simon - Westfield NJ, US
Alexander J. Thompson - Fitzroy North Victoria, AU
Thomas Urban - Durham NC, US
Dongliang Ge - Foster City CA, US
David B. Goldstein - Durham NC, US
John G. McHutchison - Chapel Hill NC, US
Ping Qiu - Edison NJ, US
Kevin Shianna - Durham NC, US
Jason S. Simon - Westfield NJ, US
Alexander J. Thompson - Fitzroy North Victoria, AU
Thomas Urban - Durham NC, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C12Q 1/68, G06F 17/18, A61K 38/21
US Classification:
424 857, 435 611, 435 5, 702 19
Abstract:
The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-α). These IFN-α response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-α pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-α, and in methods for selecting the most appropriate therapy for such patients.
Markers Associated With Ribavirin-Induced Anemia
Markers Associated With Ribavirin-Induced Anemia
US Patent:
2012028, Nov 8, 2012
Filed:
Nov 5, 2010
Appl. No.:
13/508605
Inventors:
Janice K. Albrecht - Winter Park FL, US
Clifford A. Brass - New York NY, US
Jacques Fellay - St. Maurice, CN
Dongliang Ge - Cary NC, US
David B. Goldstein - Durham NC, US
Curtis Gumbs - Durham NC, US
John G. McHutchinson - Chapel Hill NC, US
Ping Qiu - Edison NJ, US
Kevin Shianna - Durham NC, US
Alexander J. Thompson - Victoria, AU
Thomas J. Urban - Durham NC, US
Clifford A. Brass - New York NY, US
Jacques Fellay - St. Maurice, CN
Dongliang Ge - Cary NC, US
David B. Goldstein - Durham NC, US
Curtis Gumbs - Durham NC, US
John G. McHutchinson - Chapel Hill NC, US
Ping Qiu - Edison NJ, US
Kevin Shianna - Durham NC, US
Alexander J. Thompson - Victoria, AU
Thomas J. Urban - Durham NC, US
International Classification:
C12Q 1/68, A61K 38/07, A61K 38/21, A61K 38/06, A61K 31/7056, A61P 31/14
US Classification:
424 857, 514 43, 435 611, 514 43
Abstract:
The present invention provides genetic markers and biomarkers that are associated with anemia induced by ribavirin therapy. The genetic markers are located in the ITPA gene and elsewhere on human chromosome 20 and the biomarkers are low ITPA activity phenotypes. These markers of ribavirin-induced anemia are useful, inter alia, to identify patients who are least likely to develop anemia upon treatment with ribavirin pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with ribavirin, and in methods for selecting the most appropriate therapy for such patients.
Genetic Markers Associated With Interferon-Alpha Response
Genetic Markers Associated With Interferon-Alpha Response
US Patent:
8535887, Sep 17, 2013
Filed:
May 21, 2010
Appl. No.:
12/785060
Inventors:
Arthur Bertelsen - Ridgewood NJ, US
Jacques Fellay - Durham NC, US
Dongliang Ge - Raleigh NC, US
David B. Goldstein - Durham NC, US
John G. McHutchison - Chapel Hill NC, US
Ping Qiu - Edison NJ, US
Kevin Shianna - Durham NC, US
Jason S. Simon - Westfield NJ, US
Alexander J. Thompson - Durham NJ, US
Thomas Urban - Durham NC, US
Jacques Fellay - Durham NC, US
Dongliang Ge - Raleigh NC, US
David B. Goldstein - Durham NC, US
John G. McHutchison - Chapel Hill NC, US
Ping Qiu - Edison NJ, US
Kevin Shianna - Durham NC, US
Jason S. Simon - Westfield NJ, US
Alexander J. Thompson - Durham NJ, US
Thomas Urban - Durham NC, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C12Q 1/70, C12Q 1/68
US Classification:
435 611, 435 5, 435 61, 435 612
Abstract:
The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-α). These IFN-α response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-α pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-α, and in methods for selecting the most appropriate therapy for such patients.